Mereo Biopharma
Mereo Biopharma
MREO
NASDAQ
4.69
USD
42.55%
About
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS).
It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF).
Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 945.7K |
| Three Month Average Volume | 23.9M |
| High Low | |
| Fifty-Two Week High | 5.02 USD |
| Fifty-Two Week Low | 1.07 USD |
| Fifty-Two Week High Date | 23 Aug 2024 |
| Fifty-Two Week Low Date | 03 Oct 2023 |
| Price and Volume | |
| Current Price | 4.69 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 14.71% |
| Thirteen Week Relative Price Change | 27.02% |
| Twenty-Six Week Relative Price Change | 7.44% |
| Fifty-Two Week Relative Price Change | 173.20% |
| Year-to-Date Relative Price Change | 71.45% |
| Price Change | |
| One Day Price Change | 2.40% |
| Thirteen Week Price Change | 35.94% |
| Twenty-Six Week Price Change | 18.14% |
| Five Day Price Change | -2.90% |
| Fifty-Two Week Price Change | 242.34% |
| Year-to-Date Price Change | 103.03% |
| Month-to-Date Price Change | 15.52% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.46148 USD |
| Book Value Per Share (Most Recent Quarter) | 0.46148 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.35735 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.35735 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.31967 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.07876 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.07876 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.33025 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.32559 USD |
| Normalized (Last Fiscal Year) | -0.33025 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.33025 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.32559 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.33025 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.32559 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.42213 USD |
| Cash Per Share (Most Recent Quarter) | 0.42213 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.3218 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.3218 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.17546 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -308 |
| Cash Flow Revenue (Trailing Twelve Months) | -223 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -437.79% |
| Pretax Margin (Last Fiscal Year) | -437.79% |
| Pretax Margin (5 Year) | -592.88% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -50.81% |
| Gross Margin (Trailing Twelve Months) | -50.81% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -416.58% |
| Operating Margin (Trailing Twelve Months) | -416.58% |
| Operating Margin (5 Year) | -391.01% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -419.28% |
| Net Profit Margin (Trailing Twelve Months) | -419.28% |
| Net Profit Margin (5 Year) | -568.22% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -41.56% |
| EPS Change (Trailing Twelve Months) | 10.50% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 14 |
| Price to Tangible Book (Most Recent Quarter) | 14 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -52,455,210 |
| Net Debt (Last Fiscal Year) | -52,455,210 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 69 |
| Price to Sales (Trailing Twelve Months) | 69 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 10 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 10 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 10 |
| Price to Book (Most Recent Quarter) | 10 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 9 |
| Long Term Debt to Equity (Most Recent Quarter) | 9 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 7 |
| Current Ratio (Most Recent Quarter) | 7 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -23,141,040 |
| Free Cash Flow (Trailing Twelve Months) | -23,141,040 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -21 |
| Net Interest Coverage (Trailing Twelve Months) | -21 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 10 |
| Total Debt to Equity (Most Recent Quarter) | 10 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -45.26% |
| Return on Assets (Trailing Twelve Months) | -45.26% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -59.33% |
| Return on Equity (Trailing Twelve Months) | -59.33% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -55.89% |
| Return on Investment (Trailing Twelve Months) | -55.89% |
| Return on Investment (5 Year) | -99,999.99% |